<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01555073</url>
  </required_header>
  <id_info>
    <org_study_id>STU00004604</org_study_id>
    <nct_id>NCT01555073</nct_id>
  </id_info>
  <brief_title>Preemptive Analgesia Following Uterine Artery Embolization</brief_title>
  <official_title>A Prospective Randomized Blinded Placebo Controlled Comparison of Multimodal Pre-emptive Analgesia on Long Term Outcome Following Uterine Artery Embolization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uterine leiomyomata, also known as fibroids, are an extremely common benign lesion being
      present in 30-50% of all women. Traditional surgical treatment of symptomatic fibroids has
      been hysterectomy in post child bearing woman. However, over the last decade, the use of a
      minimal invasive technique called uterine artery embolization has become increasingly popular
      due to high patient satisfaction, cost effectiveness, and shorter recovery period. The
      purpose of this randomized blinded placebo controlled study is to compare pre-emptive
      analgesia vs non-preemptive analgesia for immediate postoperative pain control, long term
      pain control, and improved quality of life in woman following uterine artery embolization
      surgery. The study consists of four drug groups including a placebo group. The addition of
      pregabalin and celecoxib together with epidural analgesia may improve pain management as well
      as leading to a better post-procedure outcome in women following uterine artery embolization.

      Many investigators believe that the ischemia in the normal myometrium is the primary source
      of pain immediately following surgery making postoperative pain management challenging.
      Epidural fentanyl may offer an advantage when encountering visceral pain. In addition to
      being an effective analgesic for chronic pain syndromes, the use of pregabalin provides
      effective postoperative analgesia when it is administered pre-emptively before an operation.
      Preemptive analgesia involves the introduction of an analgesic regimen before the onset of
      noxious stimuli, with the goal of preventing sensitization of the nervous system to
      subsequent stimuli that could amplify pain. In human trials, pregabalin has been demonstrated
      to reduce pain, improve sleep, and mood disturbances in patients with post herpetic
      neuralgia. The use of celecoxib in combination with pregabalin has shown to provide more
      effective analgesia by providing antihyperalgesia. Therefore, the addition of pregabalin and
      celecoxib together with epidural analgesia may improve pain management as well as having an
      effect on long term sequelae.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Subjects did not meet inclusion criteria
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post Operative Pain Control</measure>
    <time_frame>Expected average of 12 weeks</time_frame>
    <description>To evaluate the post operative pain control of the four groups in immediate postoperative period and months following uterine artery embolisation procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Expected average of 12 weeks</time_frame>
    <description>To register the quality of life of patients receiving the four study arms following uterine artery embolisation during immediate and long term time periods.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Uterine Fibroids</condition>
  <condition>Uterine Artery Embolization</condition>
  <arm_group>
    <arm_group_label>Pregabalin/celecoxib group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pregabalin/celecoxib twice a day for 13 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin/placebo group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pregabalin/placebo twice a day for 13 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib/placebo group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>celecoxib/placebo twice a day for 13 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group, two placebo tablets day of surgery and twice a day for 13 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin/celecoxib</intervention_name>
    <description>pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.</description>
    <arm_group_label>Pregabalin/celecoxib group</arm_group_label>
    <other_name>Celebrex</other_name>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin/placebo</intervention_name>
    <description>pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.</description>
    <arm_group_label>Pregabalin/placebo group</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib/placebo</intervention_name>
    <description>celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.</description>
    <arm_group_label>Celecoxib/placebo group</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo group</intervention_name>
    <description>Placebo group, two placebo tablets day of surgery and twice a day for 13 days</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult female patients (&gt;18 years of age) who are undergoing elective uterine artery
             embolization will be included in the study.

        Exclusion Criteria:

          -  Exclusion criteria for the study are patient refusal to be included in the study, the
             presence of language barrier that inhibits proper communication with the patient

          -  Contraindications to regional anesthesia

          -  History of allergy to amide local anesthetics or narcotics

          -  Known hypersensitivity to pregabalin, creatinine clearance â‰¤ 60 mL/min

          -  The presence of a progressive neurological deficit

          -  The presence of chronic opioid analgesia

          -  The presence of a coagulopathy or infection, pregnancy

          -  Patients with cardiovascular disease

          -  Patients who take daily antiplatelet medications, patients with peptic ulcer disease

          -  History of psychiatric disorder or inability to follow study protocol.

          -  Dropout criteria include failed epidural analgesia, inability to tolerate side effects
             (nausea) from pregabalin, and the inability to contact during follow up.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <results_first_submitted>September 11, 2014</results_first_submitted>
  <results_first_submitted_qc>September 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 18, 2014</results_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Antoun Nader</investigator_full_name>
    <investigator_title>Professor in Anesthesiology and Orthopaedic Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pregabalin/Celecoxib Group</title>
          <description>pregabalin/celecoxib twice a day for 13 days.
pregabalin/celecoxib: pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.</description>
        </group>
        <group group_id="P2">
          <title>Pregabalin/Placebo Group</title>
          <description>pregabalin/placebo twice a day for 13 days.
pregabalin/placebo: pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.</description>
        </group>
        <group group_id="P3">
          <title>Celecoxib/Placebo Group</title>
          <description>celecoxib/placebo twice a day for 13 days.
celecoxib/placebo: celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.</description>
        </group>
        <group group_id="P4">
          <title>Placebo Group</title>
          <description>Placebo group, two placebo tablets day of surgery and twice a day for 13 days
Placebo group: Placebo group, two placebo tablets day of surgery and twice a day for 13 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Analysis population description</population>
      <group_list>
        <group group_id="B1">
          <title>Pregabalin/Celecoxib Group</title>
          <description>pregabalin/celecoxib twice a day for 13 days.
pregabalin/celecoxib: pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.</description>
        </group>
        <group group_id="B2">
          <title>Pregabalin/Placebo Group</title>
          <description>pregabalin/placebo twice a day for 13 days.
pregabalin/placebo: pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.</description>
        </group>
        <group group_id="B3">
          <title>Celecoxib/Placebo Group</title>
          <description>celecoxib/placebo twice a day for 13 days.
celecoxib/placebo: celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.</description>
        </group>
        <group group_id="B4">
          <title>Placebo Group</title>
          <description>Placebo group, two placebo tablets day of surgery and twice a day for 13 days
Placebo group: Placebo group, two placebo tablets day of surgery and twice a day for 13 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post Operative Pain Control</title>
        <description>To evaluate the post operative pain control of the four groups in immediate postoperative period and months following uterine artery embolisation procedure.</description>
        <time_frame>Expected average of 12 weeks</time_frame>
        <population>Early termination due to lost of follow-up for primary outcome at 3 months</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin/Celecoxib Group</title>
            <description>pregabalin/celecoxib twice a day for 13 days.
pregabalin/celecoxib: pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin/Placebo Group</title>
            <description>pregabalin/placebo twice a day for 13 days.
pregabalin/placebo: pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.</description>
          </group>
          <group group_id="O3">
            <title>Celecoxib/Placebo Group</title>
            <description>celecoxib/placebo twice a day for 13 days.
celecoxib/placebo: celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Placebo group, two placebo tablets day of surgery and twice a day for 13 days
Placebo group: Placebo group, two placebo tablets day of surgery and twice a day for 13 days</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Pain Control</title>
          <description>To evaluate the post operative pain control of the four groups in immediate postoperative period and months following uterine artery embolisation procedure.</description>
          <population>Early termination due to lost of follow-up for primary outcome at 3 months</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>To register the quality of life of patients receiving the four study arms following uterine artery embolisation during immediate and long term time periods.</description>
        <time_frame>Expected average of 12 weeks</time_frame>
        <population>Early termination due to lost of follow-up for primary outcome at 3 months</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin/Celecoxib Group</title>
            <description>pregabalin/celecoxib twice a day for 13 days.
pregabalin/celecoxib: pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin/Placebo Group</title>
            <description>pregabalin/placebo twice a day for 13 days.
pregabalin/placebo: pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.</description>
          </group>
          <group group_id="O3">
            <title>Celecoxib/Placebo Group</title>
            <description>celecoxib/placebo twice a day for 13 days.
celecoxib/placebo: celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>Placebo group, two placebo tablets day of surgery and twice a day for 13 days
Placebo group: Placebo group, two placebo tablets day of surgery and twice a day for 13 days</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>To register the quality of life of patients receiving the four study arms following uterine artery embolisation during immediate and long term time periods.</description>
          <population>Early termination due to lost of follow-up for primary outcome at 3 months</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pregabalin/Celecoxib Group</title>
          <description>pregabalin/celecoxib twice a day for 13 days.
pregabalin/celecoxib: pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.</description>
        </group>
        <group group_id="E2">
          <title>Pregabalin/Placebo Group</title>
          <description>pregabalin/placebo twice a day for 13 days.
pregabalin/placebo: pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.</description>
        </group>
        <group group_id="E3">
          <title>Celecoxib/Placebo Group</title>
          <description>celecoxib/placebo twice a day for 13 days.
celecoxib/placebo: celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Group</title>
          <description>Placebo group, two placebo tablets day of surgery and twice a day for 13 days
Placebo group: Placebo group, two placebo tablets day of surgery and twice a day for 13 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to lost of follow-up for primary outcome at 3 months</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Antoun Nader, MD</name_or_title>
      <organization>Northwestern University, Feinberg School of Medicine</organization>
      <phone>312-695-3045</phone>
      <email>a-nader2@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

